Document:

EXHIBIT 10.69

RESTRICTED STOCK
AGREEMENT

Non-transferable

GRANT TO

T. LEE PROVOW
(“Grantee”)

by Premiere Global Services, Inc. (the
“Company”) of

21,924

shares of its common stock, $0.01 par value
(the “Shares”)

pursuant to
and subject to the provisions of the Premiere Global Services, Inc. 1995 Stock
Plan, as amended (the “Plan”) and to the terms and conditions set forth on the
following page (the “Terms and Conditions”).

          Unless
sooner vested in accordance with Section 3 of the Terms and Conditions, the
restrictions imposed under Section 2 of the Terms and Conditions will expire on
December 31, 2007, provided that Grantee is then still employed by the Company
or any of its Affiliates.

          IN
WITNESS WHEREOF, Premiere Global Services, Inc., acting by and through its duly
authorized officers, has caused this Agreement to be executed as of the Grant
Date.

	
 

	
 

	
 

	
 

	
PREMIERE
  GLOBAL SERVICES, INC.

	
 

	
 

	
By:

	
 

	
 

	
 

	

	
 

	
 

	
L. Scott
  Askins

	
 

	
Its:

	
SVP –
  Legal and General Counsel

	
 

	
 

	
 

	
 

	
Grant Date:
  January 22, 2007

	
 

	
 

	
 

	
Accepted by
  Grantee:

	
 

	

Grant Date 

TERMS AND CONDITIONS

1. Grant of
Shares. Premiere Global Services, Inc. (the “Company”) hereby grants to the
Grantee named on Page 1 hereof (“Grantee”), subject to the restrictions and the
other terms and conditions set forth in the Premiere Global Services, Inc. 1995
Stock Plan, as amended (the “Plan”) and in this award agreement (this
“Agreement”), the number of shares indicated on Page 1 hereof of the Company’s
$0.01 par value common stock (the “Shares”). Capitalized terms used herein and
not otherwise defined shall have the meanings assigned to such terms in the
Plan.

2. Restrictions.
The Shares are subject to each of the following restrictions. “Restricted
Shares” mean those Shares that are subject to the restrictions imposed
hereunder which restrictions have not then expired or terminated. Restricted
Shares may not be sold, transferred, exchanged, assigned, pledged, hypothecated
or otherwise encumbered. If Grantee’s employment with the Company or any
Affiliate terminates for any reason other than as set forth in paragraphs (b),
(c) or (d) of Section 3 hereof, then Grantee shall forfeit all of Grantee’s
right, title and interest in and to the Restricted Shares as of the date of
employment termination, such Restricted Shares shall revert to the Company
immediately following the event of forfeiture. The restrictions imposed under
this Section 2 shall apply to all shares of the Company’s common stock or other
securities issued with respect to Restricted Shares hereunder in connection
with any merger, reorganization, consolidation, recapitalization, stock
dividend or other change in corporate structure affecting the common stock of
the Company.

3. Expiration and
Termination of Restrictions. The restrictions imposed under Section 2 will
expire on the earliest to occur of the following (the period prior to such
expiration being referred to herein as the “Restricted Period”):

          (a)
As to the number of Shares on the respective date specified on Page 1 hereof;
provided Grantee is then still employed by the Company or an Affiliate; 

          (b)
As to all of the unvested Shares, on the date of termination of Grantee’s
employment by reason of death or disability; 

          (c)
As to all of the unvested Shares, upon the occurrence of a “Change in Control”
(as such term is defined below); or 

          (d)
As to all of the unvested Shares, on the date of termination of Grantee’s
employment by the Company without “Cause” (as such term is defined below). 

For purposes of this
Agreement, “Cause” and “Change in Control” shall have the meaning as set forth
in Grantee’s employment agreement with the Company or any of its Affiliates, as
in effect from time to time.

4. Delivery
of Shares. The Shares will be registered in the name of Grantee as of the
Grant Date and will be held by the Company during the Restricted Period in
certificated or uncertificated form. If a certificate for Restricted Shares is
issued during the Restricted Period with respect to such Shares, such
certificate shall be registered in the name of Grantee and shall bear a legend
in substantially the following form (in addition to any legend required under
applicable state securities laws):

“This
certificate and the shares of stock represented hereby are subject to the terms
and conditions (including forfeiture and restrictions against transfer)
contained in a Restricted Stock Agreement between the registered owner of the
shares represented hereby and Premiere Global Services, Inc. Release from such
terms and conditions shall be made only in accordance with the provisions of
such Agreement, copies of which are on file in the offices of Premiere Global
Services, Inc.”

Stock
certificates for the Shares, without the first above legend, shall be delivered
to Grantee or Grantee’s designee upon request of Grantee after the expiration
of the Restricted Period, but delivery may be postponed for such period as may
be required for the Company with reasonable diligence to comply if deemed
advisable by the Company, with registration requirements under the Securities
Act of 1933, as amended, listing requirements under the rules of any stock
exchange, and requirements under any other law or regulation applicable to the
issuance or transfer of the Shares.

5. Voting
and Dividend Rights. Grantee, as beneficial owner of the Shares, shall have
full voting and dividend rights with respect to the Shares during and after the
Restricted Period. If Grantee forfeits any rights he or she may have under this
Agreement in accordance with Section 3, Grantee shall no longer have any rights
as a shareholder with respect to the Restricted Shares or any interest therein
and Grantee shall no longer be entitled to receive dividends on such stock. In
the event that for any reason Grantee shall have received dividends upon such
stock after such forfeiture, Grantee shall repay to the Company any amount
equal to such dividends.

6. Changes
in Capital Structure. The provisions of the Plan shall apply in the case of
a change in the capital structure of the Company. Without limiting the
foregoing, in the event of a subdivision of the outstanding Stock
(stock-split), a declaration of a dividend payable in Stock, or a combination
or consolidation of the outstanding Stock into a lesser number of shares, the
Shares then subject to this Agreement shall automatically be adjusted
proportionately.

7. No Right
of Continued Employment. Nothing in this Agreement shall interfere with or
limit in any way the right of the Company or any Affiliate to terminate
Grantee’s employment at any time, nor confer upon Grantee any right to continue
in the employ of the Company or any Affiliate.

8. Payment
of Taxes. Upon issuance of the Shares hereunder, Grantee may make an
election to be taxed upon such award under Section 83(b) of the Code. To effect
such election, Grantee may file an appropriate election with Internal Revenue
Service within thirty (30) days after award of the Shares and otherwise in
accordance with applicable Treasury Regulations. Grantee will, no later than
the date as of which any amount related to the Shares first becomes includable
in Grantee’s gross income for federal income tax purposes, pay to the Company,
or make other arrangements satisfactory to the Committee, regarding payment of,
any federal, state and local taxes of any kind required by law to be withheld
with respect to such amount. The obligations of the Company under this
Agreement will be conditional on such payment or arrangements, and the Company,
and, where applicable, its Affiliates will, to the extent permitted by law,
have the right to deduct any such taxes from any payment of any kind otherwise
due to Grantee.

9. Amendment.
The Committee may amend, modify or terminate this Agreement without approval of
Grantee; provided, however, that such amendment, modification or termination
shall not, without Grantee’s consent, reduce or diminish the value of this
award determined as if it had been fully vested (i.e., as if all restrictions
on the Shares hereunder had expired) on the date of such amendment or termination.

10. Plan
Controls. The terms contained in the Plan are incorporated into and made a
part of this Agreement and this Agreement shall be governed by and construed in
accordance with the Plan. In the event of any actual or alleged conflict
between the provisions of the Plan and the provisions of this Agreement, the
provisions of the Plan shall be controlling and determinative.

11. Successors.
This Agreement shall be binding upon any successor of the Company, in
accordance with the terms of this Agreement and the Plan.

12. Severability.
If any one or more of the provisions contained in this Agreement is deemed to
be invalid, illegal or unenforceable, the other provisions of this Agreement
will be construed and enforced as if the invalid, illegal or unenforceable
provision had never been included.

13. Notice.
Notices and communications under this Agreement must be in writing and either
personally delivered or sent by registered or certified United States mail,
return receipt requested, postage prepaid. Notices to the Company must be
addressed to:

	
 

	
 

	
 

	
Premiere
  Global Services, Inc.

	
 

	
3399
  Peachtree Road, N.E.

	
 

	
The Lenox
  Building, Suite 700

	
 

	
Atlanta,
  Georgia 30326

	
 

	
Attn:
  Director, Stock Plan Management

or any other address designated
by the Company in a written notice to Grantee. Notices to Grantee will be
directed to the address of Grantee then currently on file with the Company, or
at any other address given by Grantee in a written notice to the Company.

2exv10w24

 

EXHIBIT 10.24

Patent Purchase Agreement

     THIS PATENT PURCHASE AGREEMENT (“Agreement”) is entered into as of
June 21, 2002 (“Effective Date”), by and between NuVasive, Inc., a Delaware corporation
(“Buyer” or “NuVasive”) and Dr. Anthony Ross and Dr. Peter Guagliano (“Sellers”). Buyer and Seller
agree as follows:

Recitals

     1.      Sellers are the owners of the entire right, title, and interest in and to U.S.
Patent Nos. 6,183,518, 6,206,921 and 6,264,659 and US Patent Applications Ser. No. 09/659,807 and
09/990,174 (“Patent Rights”) involving compositions and related instrumentation for disc nucleus
augmentation, collectively “Disc Augmentation Technology.”

     2.      Subject to the terms and conditions of this Agreement, Buyer wishes to purchase
the Patent Rights from Sellers, and Sellers wish to sell, transfer, and convey the Patent Rights to
Buyer.

     NOW, THEREFORE, the parties hereto hereby agree as follows:

Agreement

Section 1

Purchase and Sale of the Patent Rights

     1.1     Subject to the terms and conditions of this Agreement, Sellers shall, upon successful
completion of Biomechanical Testing of the Disc Augmentation Technology (as determined in good
faith by Buyer), sell, transfer, convey, and assign the Patent Rights to Buyer in consideration of
Sellers’ receipt, on the Effective Date, of a one-time Patent Purchase Payment of Thirty Five
Thousand Dollars ($35,000) and stock options to purchase Fifty Thousand (50,000) shares of Buyer’s
common stock (“Stock Options”) pursuant to its 1998 Stock Option/Stock Issuance Plan attached
hereto as Exhibit A (the “Plan”) and subject to the Stock Option Agreement attached hereto as
Exhibit B (the “Option Agreement”) and the Stock Purchase Agreement attached hereto as Exhibit C
(the “Purchase Agreement”).

     1.2     Said Stock Options shall include a per-share price of Twenty-Five Cents ($0.25) and shall
vest according to the vesting schedule set forth in the Grant Notice attached hereto as Exhibit D
(the “Grant Notice”) or until such time as the Biomechanical Testing is successfully completed, at
which point any unvested shares shall become fully vested.

     1.3     In the instance the Biomechanical Testing is NOT successfully completed ownership of the
Patent Rights shall remain with the Sellers and Sellers shall retain the one-time
Patent Purchase Payment of Thirty-Five Thousand Dollars ($35,000) and all Stock Options
already vested.

 

 

Section 2

Delivery

     2.1     On the Effective Date, Buyer will deliver to Sellers the Stock Options and the Patent
Purchase Payment as set forth in Section 1.1.

     2.2     Upon successful completion of the Biomechanical Testing, Sellers agree to execute and
deliver to Buyer an Assignment of Patent Rights substantially in the form of Exhibit E attached
hereto (the “Assignment Agreement”).

Section 3

Representations, Warranties, and Covenants of Sellers

     Sellers hereby represent, warrant, and covenant to Buyer as follows:

     3.1     No Public Market. Sellers understand that no public market now exists for any of the
securities issued to Buyer and that there is no assurance that a public market will ever exist for
the Shares.

     3.2     Authorization. Sellers represent that they have the full right, power, and authority to
enter into and perform their obligations under this Agreement and the Assignment Agreement
(collectively, the “Agreements”). Sellers agree that the Agreements, when executed and delivered
by Sellers, will constitute valid and binding conveyances and obligations of Sellers, enforceable
in accordance with their terms, subject to the laws of general application relating to bankruptcy,
insolvency, and the relief of debtors, rules of law governing specific performance, injunctive
relief, or other equitable remedies.

     3.3     Consents. Other than filings required by Buyer and compliance with the registration
requirements of applicable federal and state securities laws, or exemptions therefrom, no consent,
approval, or authorization of or designation, declaration or filing with any state, federal, or
foreign governmental authority, or any third party, on the part of Sellers is required in
connection with the valid execution and delivery of the Agreements by Sellers, and the consummation
of the transactions contemplated hereby.

     3.4     Ownership of the Patent Rights. Sellers are the owners of the entire right, title, and
interest in the Patent Rights, and Sellers have not previously assigned or licensed the Patent
Rights (nor will they until the Biomechanical Testing is completed) and are not aware of any
infringement issues or adverse claims of ownership to the Patent Rights.

Section 4

Buyer’s Conditions to Closing

     Buyer’s obligation to purchase the Patent Rights is, at the option of Buyer, subject to
fulfillment of the following conditions:

     4.1     Representations. The representations made by Sellers in Section 3 hereof shall be true
and correct when made, and shall be true and correct on the Effective Date and at the completion of
Biomechanical Testing.

2

 

     4.2     Execution and Delivery of Assignment. Upon successful completion of the Biomechanical
Testing, Sellers shall have executed and delivered to Buyer the Assignment Agreement set forth in
Exhibit E.

     4.3     Board Approval. The Board of Directors of Buyer shall have approved the issuance of said
Stock Options.

Section 5

Grant Back of Patent Rights

     5.1     In the instance NuVasive fails to introduce a product or composition embodying Disc
Augmentation Technology (or related method) within a commercially reasonable time period, NuVasive
agrees to grant the Patent Rights back to Sellers (via an Assignment of Patent Rights substantially
in the form as shown in Exhibit E attached hereto). The determination of “commercially reasonable
time period” shall take into consideration, among other factors, the amount of time required to
obtain FDA clearance to commercialize Disc Augmentation Technology.

     5.2     Sellers agree that, as a precondition to the grant back of Patent Rights of Section 5.1,
NuVasive shall be entitled to receive all Stock Options which are unvested at the time the Patent
Rights are granted back to Sellers, to the extent such Stock Options have not yet fully vested
based on the successful completion of the Biomechanical Testing pursuant to Section 1.2.

Section 6

Miscellaneous

     6.1     Governing Law; Venue. This Agreement shall be governed in all respects by the laws of
the State of California as applied to contracts made and to be fully performed entirely within the
state between residents of California. All disputes arising out of this Agreement shall be subject
to the exclusive jurisdiction and venue of California state courts of San Diego County, California
(or, if there is exclusive federal jurisdiction, the United States District Court for the Southern
District of California) and the parties consent to the personal and exclusive jurisdiction and
venue of these courts.

     6.2     Successors and Assigns. Except as otherwise provided herein, the provisions hereof shall
inure to the benefit of, and be binding upon, the successors, assigns, heirs,, executors, and
administrators of the parties hereto.

     6.3     Indemnification by NuVasive. Buyer agrees to indemnify, defend and hold Sellers harmless
from any third party liability, losses, damages, or costs (including reasonable attorneys’ fees and
costs) arising out of or related to any action arising out of (a) a claim that the manufacture or
sale of any Disc Augmentation Technology violates the patent, trademark, or trade name rights of
any third party; (b) any alleged defects or failures to perform of the Disc Augmentation
Technology; (c) any product liability claims or use of the Disc Augmentation
Technology; or (d) the advertising, distribution or marketing of the Disc Augmentation
Technology. Sellers agree to assist Buyer in the defense of any such action set forth in 6.3(a)
through 6.3(d).

3

 

     6.4     Enforcement. In the event that NuVasive wishes to enforce Patent Rights against a third
party infringer, Sellers will provide reasonable cooperation and assistance in that effort,
including being available for witness and deposition testimony, making documents available, and
complying with any other reasonable request.

     6.5     Insurance. NuVasive agrees to maintain product liability insurance coverage of at least
$3 million per occurrence and to name Drs. Anthony Ross and Peter Guagliano as additional insureds
thereunder.

     6.6     Entire Agreement; Amendment. This Agreement and the other documents delivered pursuant
hereto constitute the full and entire understanding and agreement between the parties with regard
to the subjects hereof and thereof and supersede all prior arrangements and understanding with
respect hereto. Neither this Agreement nor any term hereof may be amended, waived, discharged, or
terminated other than by a written instrument signed by Buyer and Sellers.

     6.7     Notices. Any notice or communication required or permitted to be given under this
Agreement shall be sufficiently given when received by certified mail, or by overnight courier, to
the parties at the addresses provided below.

     6.8     Severability. In the event that any provision of this Agreement becomes or is declared by
a court of competent jurisdiction to be illegal, unenforceable, or void, this Agreement shall
continue in full force and effect without said provision; provided that no such severability shall
be effective if it materially changes the economic benefit of this Agreement to any party.

4

 

     The foregoing Patent Purchase Agreement is hereby executed by Buyer and Sellers as of the date
first above written.

	 	 	 	 	 	 	 	 	 
	Buyer:	 	 	 	Sellers:
	 
	 	 	 	 	 	 	 	 
	NuVasive, Inc.	 	 	 	Dr. Anthony C. Ross
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Alexis Lukianov
	 	 	 	By:
	 	/s/ Anthony Ross
	 

	 	 
	 	 	 	 	 	 
	 

	 	ALEXIS V. LUKIANOV
	 	 	 	 	 	ANTHONY C. ROSS
	 

	 	President & CEO
	 	 	 	 	 	An individual
	 

	 	NuVasive, Inc.
	 	 	 	 	 	Anthony C. Ross, D.C.
	 

	 	10065 Old Grove Road
	 	 	 	 	 	3546 Maybank Hwy.
	 

	 	San Diego, California 92131
	 	 	 	 	 	John’s Island, S.C. 29455
	 
	 	 	 	 	 	 	 	 
	Date:

	 	6-24-02
	 	 	 	Date:
	 	 6/21/02
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Dr. Peter A. Guagliano
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	By:
	 	/s/ Peter Guagliano
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	PETER A. GUAGLIANO
	 

	 	 	 	 	 	 	 	An individual
	 

	 	 	 	 	 	 	 	370 Bay Ridge Parkway
	 

	 	 	 	 	 	 	 	Brooklyn, NY 11209
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Date:
	 	6/21/02
	 

	 	 	 	 	 	 	 	 

 

 

EXHIBIT A

1998 NuVasive Stock Option/Stock Issuance Plan

 

 

EXHIBIT B

NuVasive Stock Option Agreement

 

 

EXHIBIT C

Stock Purchase Agreement

 

 

EXHIBIT D

Grant Notice

 

 

EXHIBIT E

Assignment of Patent Rights

     In consideration of the mutual obligations set forth in that Patent Purchase Agreement dated
___by and between NuVasive, Inc. (“NuVasive”) and Drs. Anthony C. Ross and Peter
A. Guagliano (“Drs. Ross and Guagliano”), the adequacy and receipt of which is hereby acknowledged,
Dr. Ross and Guagliano, owners of the entire right, title, and interest in and to U.S. Patent Nos.
6,183,518, 6,206,921 and 6,264,659 and US Patent Applications Ser. No. 09/659,807 and 09/990,174
(“Patent Rights”) hereby sell and assign to NuVasive the entire right, title and interest in the
Patent Rights, to be held and enjoyed by NuVasive, its successors and assigns, as fully and
entirely as the same would have been held and enjoyed by Drs. Ross and Guagliano had this
assignment and sale not been made.

     In testimony whereof, Dr. Anthony C. Ross and Dr. Peter A. Guagliano have signed this
Assignment of Patent Rights this ___day of ___, 2002.

_________________________

[seal]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]